



OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations.

Visit go.covermymeds.com/OptumRx to begin using this free service.

Please note: All information below is required to process this request.

Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific

Kineret® Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
Select the diagnosis below:					
<input type="checkbox"/> Moderately to severely active rheumatoid arthritis					
<input type="checkbox"/> Neonatal-onset multisystem inflammatory disease (NOMID)					
<input type="checkbox"/> Systemic juvenile idiopathic arthritis (SJIA)					
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
Clinical Information:					
Will the patient be using Kineret in combination with a biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Select if Kineret is prescribed by or in consultation with one of the following specialists:					
<input type="checkbox"/> Allergist/Immunologist <input type="checkbox"/> Rheumatologist					
For moderately to severely active rheumatoid arthritis, also answer the following:					
Has the patient had a trial and failure, contraindication, or intolerance to one non-biologic disease modifying anti-rheumatic drug (DMARD) [e.g., Rheumatrex/Trexall (methotrexate), Arava (leflunomide), Azulfidine (sulfasalazine)]? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Is this request for continuation of prior Kineret therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Select if the patient has had a trial and failure, contraindication, or intolerance to the following, or attestation demonstrating a trial may be inappropriate:					
<input type="checkbox"/> Cimzia (certolizumab)					
<input type="checkbox"/> Humira (adalimumab)					
<input type="checkbox"/> Simponi (golimumab) or Simponi Aria (golimumab IV)					
Select if the patient has had a trial and failure, contraindication, or intolerance to the following:					
<input type="checkbox"/> Kevzara (sarilumab)					
<input type="checkbox"/> Xeljanz (tofacitinib) or Xeljanz XR (tofacitinib ER)					
For neonatal-onset multisystem inflammatory disease (NOMID), also answer the following:					
Select if the patient has a diagnosis of NOMID as confirmed by the following:					
<input type="checkbox"/> NLRP-3 [nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3 gene (also known as cold-induced auto-inflammatory syndrome-1 [CIAS1]) mutation					
<input type="checkbox"/> Evidence of active inflammation which includes clinical symptoms (e.g., rash, fever, arthralgia)					
<input type="checkbox"/> Evidence of active inflammation which includes elevated acute phase reactants (e.g., ESR, CRP)					

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Office use only: Kineret_Comm_2018Feb-W



Kineret® Prior Authorization Request Form (Page 2 of 2)
DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

For systemic juvenile idiopathic arthritis (SJIA), also answer the following:

Does the patient have active SJIA? Yes No

Has the patient had a trial and failure, contraindication, or intolerance to a non-steroidal anti-inflammatory drug (NSAID) [e.g., Motrin (ibuprofen), Naprosyn (naproxen)]? Yes No

Has the patient had a trial and failure, contraindication, or intolerance to a systemic glucocorticoid (e.g., prednisone)? Yes No

Reauthorization:

If this is a reauthorization request, answer the following questions:

Is there documentation the patient has had a positive clinical response to Kineret therapy? Yes No

Is the patient receiving Kineret in combination with a biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]? Yes No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note:

This request may be denied unless all required information is received.

For urgent or expedited requests please call 1-800-711-4555.

This form may be used for non-urgent requests and faxed to 1-800-527-0531.